Description
For years, cell biologists have relied on classic growth media, like Dulbecco Modified Eagle's Medium (DMEM), MCDB-105 and RPMI 1640. With scores of publications to their names, these time-proven standbys continue to form a sound foundation for in vitro culture experiments.
Add supplements such as fetal bovine serum, growth factors, trace elements, and /or antibiotics, depending on cell type. The media are buffered and sterile filtered, and tested to stringent quality standards.
Classic Cell Culture Media, e.g. Dulbecco Modified Eagle's Medium (DMEM), MCDB-105 and RPMI 1640.
Details
Need help choosing? See our Media Selection Guide
Products
| Product | Size | CAT.# | Price | Quantity |
|---|---|---|---|---|
| MCDB 105 Medium, Unmodified: Unmodified MCDB 105 Medium | Size: 500 ml | CAT.#: 117-500 | Price: $68.00 | |
| DMEM Medium: 1X DMEM, 4.25g/L Glucose | Size: 500 ml | CAT.#: 180-500 | Price: $26.00 | |
| RPMI 1640 w/L-Glutamine Medium: RPMI 1640 Medium, with L-Glutamine, without HEPES | Size: 500 ml | CAT.#: 185-500 | Price: $27.00 |
Related Products
| Product | Size | CAT.# | Price | Quantity |
|---|---|---|---|---|
| L-Glutamine: Amino acid supplement for cell culture media, important for cell growth & function | Size: 100 ml | CAT.#: 013-100 | Price: $38.00 |
Publications
2017
Liao, Y., Y. Deng, J. Liu, Z. Ye, Z. You, S. Yao and S. He. 2017. MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression. Gynecologic Oncology, 143:655-663.
Muranen, T., M.Iwanicki, N. Curry, J. Hwang, C. DuBois,J. Coloff, D. Hitchcock, C. Clish, J. Brugge and N. Kalaany. 2017. Starved epithelial cells uptake extracellular matrix for survival. Nature Commumicatins, 8: doi:10.1038/ncomms13989.
2016
Guo, T., G. Shen, X. Tong, G. Zhou, Y. Wan, D. Li, X. Dai, X. Sun and Y. Tian. 2016. miR-125b expression in ovarian cancer cell lines. Int J Clin Exp Pathathol, 9:5267-5275.
Liao, Y., Y. Deng, J. Liu, Z. Ye, Z. You, S. Yao and S. He. 2016. MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression. Gynecologic Oncology, 143:655-663.
2015
Wu, B., S. Shrestha, K. Ong, D. Johns, L. Dunn, L. Hou, P. Barter and K. Rye. 2015. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis. Intl J Cardiol, 199:204-212.
Zhu, Z., L. Song, J. He, Y. Sun, X. Liu and X. Zou. 2015. Ectopic expressed long non-coding RNA H19 contributes to malignant cell behavior of ovarian cancer. Int J Clin Exp Pathol, 8:10082-10091.
2014
Davidowitz, R., L. Selfors, M. Iwanicki, K. Elias, A. Karst, H. Piao, T. Ince, M. Drage, J. Dering, G. Konecny, U. Matulonis, G. Mills, D. Slamon, R. Drapkin and J. Brugge. 2014. Mesenchymal gene program–expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest, 124:2611–2625.
Stein, J., C. Iwuchukwu, K. Maier and V. Gahtan. 2014. Thrombospondin-1−induced vascular smooth muscle cell migration and proliferation are functionally dependent on microRNA-21. Surgery, 155:228-233.
2012
Meng, E., B. Long, P. Sullivan, S. McClellan, M. Finan, E. Reed, L. Shevde, and R. Rocconi. 2012. CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin & Exp Met, 29:939-948.
Moffett, J., L.M. Fray, and N.J. Kubat. 2012. Activation of endogenous opioid gene expression in human keratinocytes and fibroblasts by pulsed radiofrequency energy fields. Journal of pain research. 5:347.
2011
Iwanicki, M., R. Davidowitz, M. Ng, A. Besser, T. Muranen, M. Merritt, G. Danuser, T. Ince, and J. Brugge. 2011. Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium. Cancer Discovery, 1:144.
Ray, A., E. Meng, E. Reed, L. Shevde, andn R. Rocconi. 2011. Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. Intl J Oncol, 39:797-804.
2009
Konecny, G., R. Glas, J. Dering, K. Manivong, J. Qi, R. Finn, G. Yang, K. Hong, C. Ginther, B. Winterhoff, G. Gao, J. Brugge, and D. Slamon. 2009. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. British J Cancer, 101:1699-1708